Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06268769
Other study ID # TaC:Drop
Secondary ID 2023-503531-18-0
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 9, 2024
Est. completion date September 2029

Study information

Verified date May 2024
Source University of Regensburg
Contact Edward K. Geissler, PhD
Phone +49 941 944
Email edward.geissler@ukr.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.


Description:

This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability. The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time. Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters. Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date September 2029
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed and dated written informed consent 2. Adult (=18 years old) male or female 3. Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor 4. ABO blood type compatible with the donor kidney 5. Able to swallow an oral formulation of tacrolimus in tablet or capsule form Exclusion Criteria: 1. Multi-organ transplantation 2. Any previous solid organ transplantation (other than a first kidney allograft) 3. For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease 4. Patient and/or donor is positive for HCV, HBV or HIV 5. History of any malignancy that could not be curatively treated 6. Ongoing abuse of drugs or alcohol 7. Signs of advanced liver disease or any signs of liver decompensation 8. Ongoing uncontrolled systemic infection 9. Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus 10. Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™ 11. Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides 12. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test 13. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception 14. Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period 15. Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule 16. Inability to freely give informed consent (e.g. individuals under legal guardianship)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tacrolimus Pill
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Tacrolimus capsule
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Locations

Country Name City State
Germany University Hospital Aachen, Department of General, Visceral and Transplant Surgery Aachen
Germany Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care Berlin
Germany University Hospital Dresden, Division of Nephrology Dresden
Germany University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology) Hamburg
Germany Hannover Medical School, Department of General, Visceral and Transplant Surgery Hannover
Germany University Hospital Jena, Internal Medicine III, Nephrology Jena
Germany University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology) Mainz
Germany University Hospital Münster, Medical Clinic D Münster
Germany University Hospital Regensburg, Department of Nephrology Regensburg

Sponsors (2)

Lead Sponsor Collaborator
Edward Geissler Chiesi Pharmaceuticals GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-normalised blood trough level of tacrolimus (concentration/dose ratio) To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory. 12 weeks after kidney transplantation
Secondary Time to reach the first trough level in target range Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading Time period measured in days, assessed within the first 2 weeks after kidney transplantation
Secondary Proportion of patients with trough levels lower, within, or higher than the target range 4 days, 14 days, 28 days and 12 weeks after kidney transplantation
Secondary Mean tacrolimus trough level and inter-patient variability (range) of tacrolimus trough levels 4 days, 14 days, 28 days and 12 weeks after kidney transplantation
Secondary Mean daily dose of tacrolimus and inter-patient variability (range) of tacrolimus daily dose 4 days, 14 days, 28 days and 12 weeks after kidney transplantation
Secondary Tacrolimus concentration/dose (C/D) ratio The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site. 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
Secondary Intra-patient variability of C/D ratio and daily dose Measured over the time points: day 4, day 14, day 28 and week 12
Secondary Treatment failure rate A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause) 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Time to treatment failure after transplantation Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause) Measured until 3 years after kidney transplantation
Secondary Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition. 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Incidence rate of graft failure Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Mortality rate Mortality rate measures death from any cause 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Graft function measured by eGFR (estimated glomerular filtration rate) eGFR calculated according to the CKD-EPI formula 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Incidence rate of for-cause biopsies 12 weeks after kidney transplantation
Secondary Incidence rate of acute rejection episodes requiring treatment 12 weeks after kidney transplantation
Secondary Incidence rate of steroid-resistant episodes of biopsy-proven acute rejection 12 weeks and 1 year after kidney transplantation
Secondary Incidence rate of delayed graft function Delayed graft function is defined as the need for more than one episode of dialysis after transplantation Measurable within the first 2 weeks after kidney transplantation
Secondary Incidence rate of primary non-function of the renal allograft Primary non-function is defined as the necessity for ongoing chronic dialysis Measurable within the first 12 weeks after kidney transplantation
Secondary Incidence of hepatotoxicity Hepatotoxicity is defined as GPT or GOT levels = 2.5 x upper limit of normal range 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Incidence of CMV and BKV infection (including organ manifestation, if relevant) 12 weeks and 1 year after kidney transplantation
Secondary Incidence, type, severity and seriousness of adverse reactions (ARs) 12 weeks and 3 years after kidney transplantation
Secondary Blood pressure 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Incidence of de novo tremor Incidence and severity of tremor based on medical assessment by the investigator 12 weeks and 3 years after kidney transplantation
Secondary Incidence of gastrointestinal disorders requiring diagnostic investigation 12 weeks and 3 years after kidney transplantation
Secondary Incidence of new onset diabetes mellitus after transplantation (NODAT) NODAT is defined as HbA1c = 6.5% or 47.5 mmol/mol or fasting plasma glucose = 126 mg/dl on two separate occasions 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Recurrence of primary kidney disease 12 weeks and 3 years after kidney transplantation
Secondary Incidence of de novo DSA Detected within the first year after kidney transplantation
Secondary Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34) The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients. 12 weeks and 3 years after kidney transplantation
Secondary Doses and duration of glucocorticosteroid treatment 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Dose of mycophenolate Including both mycophenolate mofetil and mycophenolic acid 12 weeks and 1, 2, 3 years after kidney transplantation
Secondary Incidence and time to study treatment discontinuation 3 years after kidney transplantation
Secondary Incidence, time to and reason for patient withdrawal from study 3 years after kidney transplantation
See also
  Status Clinical Trial Phase
Recruiting NCT05060991 - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients Phase 4
Completed NCT02833805 - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Phase 2
Completed NCT01252537 - Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia N/A
Completed NCT01678937 - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents N/A
Completed NCT00621699 - Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects Phase 1
Completed NCT00788021 - Protective Immunity Project 01 N/A
Active, not recruiting NCT00166842 - Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets Phase 4
Recruiting NCT05616130 - Pathological Myeloid Activation After Sepsis and Trauma
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Recruiting NCT01568697 - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Not yet recruiting NCT06024226 - Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Not yet recruiting NCT04961229 - Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response Phase 4
Completed NCT03139565 - High Dose vs. Standard Influenza Vaccine in Adult SOT Phase 3
Completed NCT02547753 - Dental Extractions Among Renal Transplant Recipients
Completed NCT01702207 - Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk Phase 4
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00419575 - Renal Transplantation With Immune Monitoring N/A
Completed NCT00783380 - Influenza Vaccination in Immunocompromized Patients Phase 4
Completed NCT04835948 - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Recruiting NCT05043870 - Combined Immunosuppression for Pediatric Crohn's Disease Phase 4